<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04794972</url>
  </required_header>
  <id_info>
    <org_study_id>GNC-039-101</org_study_id>
    <nct_id>NCT04794972</nct_id>
  </id_info>
  <brief_title>A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors</brief_title>
  <official_title>An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability，Pharmacokinetic/Pharmacodynamics and Anti-tumor Activity of Tetra-specific Antibody GNC-039 in Participants With Relapsed/Refractory or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Baili Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SystImmune Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sichuan Baili Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the safety, tolerability and preliminary effectiveness of GNC-039 in patients&#xD;
      with relapsed/refractory or metastatic glioma or other solid tumors will be investigated to&#xD;
      assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered&#xD;
      dose (MAD) for MTD is not reached of GNC-039.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 13, 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity (DLT)</measure>
    <time_frame>Time Frame: Up to 14 days after the first dose of GNC-039]</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) or maximum administrated dose (MAD)</measure>
    <time_frame>Time Frame: Up to 14 days after the first dose of GNC-039]</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment-Emergent Adverse Event (TEAE)</measure>
    <time_frame>[Time Frame: Up to approximately 24 months]</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug-related Adverse Events</measure>
    <time_frame>[Time Frame: Up to approximately 24 months]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum serum concentration of GNC-039</measure>
    <time_frame>[Time Frame: Up to 14 days after the first dose of GNC-039]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time to maximum serum concentration (Tmax) of GNC-039</measure>
    <time_frame>[Time Frame: Up to 14 days after the first dose of GNC-039]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2: Half-life of GNC-039</measure>
    <time_frame>[Time Frame: Up to 14 days after the first dose of GNC-039]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf: Area under the serum concentration-time curve from time 0 to infinity</measure>
    <time_frame>[Time Frame: Up to 14 days after the first dose of GNC-039]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t: Area under the serum concentration-time curve from time 0 to the time of the last measurable concentration</measure>
    <time_frame>[Time Frame: Up to 14 days after the first dose of GNC-039]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL: Clearance in the serum of GNC-039 per unit of time</measure>
    <time_frame>[Time Frame: Up to 14 days after the first dose of GNC-039]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and titer of ADA (Anti-drug antibody)</measure>
    <time_frame>[Time Frame: Up to approximately 24 months]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR (Objective Response Rate )</measure>
    <time_frame>[Time Frame: Up to approximately 24 months]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS (Overall Survival)</measure>
    <time_frame>[Time Frame: Up to approximately 24 months]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS (Progression-free Survival)</measure>
    <time_frame>[Time Frame: Up to approximately 24 months]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR (Duration of Response)</measure>
    <time_frame>[Time Frame: Up to approximately 24 months]</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">147</enrollment>
  <condition>Glioma</condition>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Study treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive GNC-039 as intravenous infusion for one cycle. Participants with no intolerable AEs could continue for another three cycles. Participants with a clinical benefit after four cycles' treatment could also receive additional treatment for another two cycles at the same dose level.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GNC-039</intervention_name>
    <description>Administration by intravenous infusion.</description>
    <arm_group_label>Study treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. After the failure of standard treatment (surgery, stupp regimen treatment), the&#xD;
             recurrence of high-grade glioma (WHO grade III-IV) or other relapsed/refractory or&#xD;
             metastatic solid tumor subjects could understand and consent form, voluntarily&#xD;
             participate and sign the informed consent form.&#xD;
&#xD;
          2. No gender limit.&#xD;
&#xD;
          3. Age: ≥18 years old.&#xD;
&#xD;
          4. KPS≥60 points.&#xD;
&#xD;
          5. Expected survival time ≥ 3 months.&#xD;
&#xD;
          6. Hematology function meets the following requirements: absolute neutrophil count (ANC)&#xD;
             ≥1.5×109/L, platelet count ≥100×109/L, hemoglobin ≥90g/L.&#xD;
&#xD;
          7. Renal function meets the following requirements: creatinine (Cr) ≤ 1.5 ULN and&#xD;
             creatinine clearance (Ccr) ≥ 50 mL/min (calculated by the research center), urine&#xD;
             protein ≤ 2+ or ≤ 1000 mg/24h (urine).&#xD;
&#xD;
          8. Liver function meets the following requirements: aspartate aminotransferase (AST) and&#xD;
             alanine aminotransferase (ALT) ≤3×ULN; total bilirubin ≤1.5×ULN (Gilbert's syndrome&#xD;
             ≤3×ULN).&#xD;
&#xD;
          9. Coagulation function: fibrinogen ≥1.0g/L; activated partial thromboplastin time (APTT)&#xD;
             ≤1.5×ULN; prothrombin time (PT) ≤1.5×ULN.&#xD;
&#xD;
         10. Female participants with fertility or male participants whose partner(s) are fertile&#xD;
             must take effective contraceptive measures from 7 days prior to the first&#xD;
             administration to 24 weeks after the administration. Female participants with&#xD;
             fertility must have a negative serum/urine pregnancy test in 7 days prior to the first&#xD;
             dose.&#xD;
&#xD;
         11. The participants are capable and willing to comply with the visits, treatment plans,&#xD;
             laboratory examinations and other research-related procedures stipulated in the&#xD;
             research protocol.&#xD;
&#xD;
         12. For participants with glioma:&#xD;
&#xD;
               1. There must be a pathological diagnosis of high-grade glioma;&#xD;
&#xD;
               2. MRI diagnosis supports recurrence;&#xD;
&#xD;
               3. There is at least one measurable tumor lesion according to the RANO standard; or&#xD;
                  the participants undergo surgery after recurrence;&#xD;
&#xD;
               4. Have archived tumor tissues or sections that could be submitted to the center for&#xD;
                  review for the first time or recurrence (no less than 10 pathological white films&#xD;
                  of 3-5μm should be provided).&#xD;
&#xD;
         13. For participants with other solid tumors:&#xD;
&#xD;
               1. Relapsed/refractory or metastatic solid tumor are confirmed by histology or&#xD;
                  cytology, and disease progression are confirmed by imaging or other objective&#xD;
                  evidence after receiving standard treatment; or the participants are confirmed&#xD;
                  with refractory solid tumor who cannot tolerate standard treatment or have&#xD;
                  contraindications to standard treatment;&#xD;
&#xD;
               2. Must have at least one measurable lesion that meets the definition of RECIST&#xD;
                  v1.1; the participant could understand the informed consent form and sign the&#xD;
                  informed consent form voluntarily.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        If any of the following occurs in the participants for this study, any of them should be&#xD;
        excluded:&#xD;
&#xD;
          1. Participants who are allergic to immune globulin or any component of injection&#xD;
             preparations.&#xD;
&#xD;
          2. Participants with active infections that require intravenous antibiotics and who have&#xD;
             not completed treatment 1 week prior to enrollment, except those who have used&#xD;
             prophylactic antibiotics for puncture or biopsy.&#xD;
&#xD;
          3. Human immunodeficiency virus antibody (HIVAb) positive, active tuberculosis, active&#xD;
             hepatitis B virus infection (HBV-DNA copy number ≥&gt;ULN) or hepatitis C virus (HCV)&#xD;
             infection (HCV-RNA≥ULN).&#xD;
&#xD;
          4. The toxicity of the previous anti-tumor treatment has not been reduced to the level I&#xD;
             defined in the CTCAE 4.0 version (except for symptoms related to bone marrow&#xD;
             suppression, such as neutropenia, anemia, thrombocytopenia) or the level specified in&#xD;
             the inclusion criteria, except for hair loss and irreversible toxicity from previous&#xD;
             anti-tumor treatments (defined as stable existence ≥ 2 months) permitted by the&#xD;
             investigator/sponsor's consideration.&#xD;
&#xD;
          5. Participants at risk of active autoimmune diseases, or with a history of autoimmune&#xD;
             diseases, including but not limited to Crohn's disease, ulcerative colitis, systemic&#xD;
             lupus erythematosus, sarcoidosis, Wegener syndrome (polyangiitis granuloma disease,&#xD;
             Graves' disease, rheumatoid arthritis, pituitary inflammation, uveitis), autoimmune&#xD;
             hepatitis, systemic sclerosis, Hashimoto's thyroiditis, autoimmune vasculitis,&#xD;
             autoimmune neuropathy (Guillain-Barré syndrome), etc. Except for the following&#xD;
             conditions: Type I diabetes, hormone replacement therapy for stable hypothyroidism&#xD;
             (including hypothyroidism caused by autoimmune thyroid disease), psoriasis or vitiligo&#xD;
             that does not require systemic treatment.&#xD;
&#xD;
          6. Has grade 3 or above lung disease defined according to NCI-CTCAE v5.0, including&#xD;
             resting dyspnea, or requiring continuous oxygen therapy, or a history of interstitial&#xD;
             lung disease (ILD).&#xD;
&#xD;
          7. Participants who have received organ transplants in the past.&#xD;
&#xD;
          8. Left ventricular ejection fraction ≤45%, (hypersensitivity) troponin&gt;ULN.&#xD;
&#xD;
          9. History of severe heart disease:&#xD;
&#xD;
               1. New York Heart Association (NYHA) grade III or IV congestive heart failure;&#xD;
&#xD;
               2. Have had myocardial infarction, bypass or stent surgery within 6 months prior to&#xD;
                  administration;&#xD;
&#xD;
               3. Participants who currently have unstable angina&#xD;
&#xD;
               4. Other heart diseases that the investigator judges are not suitable for including&#xD;
                  in the group;&#xD;
&#xD;
         10. Participants with prolonged QT interval (male QTc&gt; 450 msec or female QTc&gt; 470 msec),&#xD;
             complete left bundle branch block, III grade atrioventricular block.&#xD;
&#xD;
         11. Previously suffering from or accompanied by deep vein thrombosis, arterial thrombosis&#xD;
             and pulmonary embolism and other thrombotic events.&#xD;
&#xD;
         12. Other conditions that the investigator believes that it is not suitable for&#xD;
             participating in this clinical trial.&#xD;
&#xD;
         13. For glioma participants:&#xD;
&#xD;
               1. Those who have received surgery, chemotherapy, targeted and immunological drug&#xD;
                  therapy, iodine internal radiation, radiotherapy within 4 weeks prior to&#xD;
                  enrollment, or those who plan to undergo radiotherapy during the trial.&#xD;
&#xD;
               2. Participants who had undergone needle biopsy of intracranial lesions within 7&#xD;
                  days prior to enrollment&#xD;
&#xD;
               3. Those who have accept other clinical trials within 4 weeks prior to enrollment&#xD;
&#xD;
               4. Within 6 months prior to enrollment, there was a history of central nervous&#xD;
                  system hemorrhage/infarction unrelated to anticancer drugs, such as stroke or&#xD;
                  intraocular hemorrhage (including embolic stroke)&#xD;
&#xD;
         14. For other solid tumors:&#xD;
&#xD;
               1. Received anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted&#xD;
                  therapy or research drug) within 14 days of the first administration or 5&#xD;
                  half-lives (whichever is longer);&#xD;
&#xD;
               2. Participants who have undergone major surgery within 28 days prior to the&#xD;
                  administration of this study, or who are planning to undergo major surgery during&#xD;
                  the study (except for surgery such as puncture or lymph node biopsy);&#xD;
&#xD;
               3. Hypertension with poor drug control (systolic blood pressure&gt; 150 mmHg or&#xD;
                  diastolic blood pressure&gt; 100 mmHg);&#xD;
&#xD;
               4. Previously suffering from or accompanied by central nervous system diseases,&#xD;
                  including but not limited to: epilepsy, paralysis, stroke, severe brain injury,&#xD;
                  Alzheimer's, Parkinson's disease, cerebellar disease, cerebral organic syndrome,&#xD;
                  psychosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wenbin Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hai Zhu</last_name>
    <phone>+86-13980051002</phone>
    <email>zhuhai@baili-pharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sa Xiao</last_name>
    <phone>+86-15013238943</phone>
    <email>xiaosa@baili-pharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital Affiliated to Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100070</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenbin Li</last_name>
      <phone>+86-010-59975034</phone>
      <email>neure55@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhuang Kang</last_name>
      <phone>+86-15011281069</phone>
      <email>kzhaoren1984@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Wenbin Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhuang Kang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 9, 2021</study_first_submitted>
  <study_first_submitted_qc>March 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioma</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

